Cargando…

Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey

BACKGROUND: Quality of life (QOL) is a critical factor in decision-making for advanced breast cancer (ABC). There is a need to improve how QOL and treatment-related side effects (SEs) that impact it are clinically assessed. We examined healthcare professionals’ (HCPs’) and patients’ perspectives on...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardoso, Fatima, Rihani, Julie, Harmer, Victoria, Harbeck, Nadia, Casas, Ana, Rugo, Hope S, Fasching, Peter A, Moore, Adam, de Courcy, Joanna, Pathak, Purnima, Haftchenary, Sina, Aubel, Dawn, Schumacher-Wulf, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546820/
https://www.ncbi.nlm.nih.gov/pubmed/37523663
http://dx.doi.org/10.1093/oncolo/oyad207
_version_ 1785114939199848448
author Cardoso, Fatima
Rihani, Julie
Harmer, Victoria
Harbeck, Nadia
Casas, Ana
Rugo, Hope S
Fasching, Peter A
Moore, Adam
de Courcy, Joanna
Pathak, Purnima
Haftchenary, Sina
Aubel, Dawn
Schumacher-Wulf, Eva
author_facet Cardoso, Fatima
Rihani, Julie
Harmer, Victoria
Harbeck, Nadia
Casas, Ana
Rugo, Hope S
Fasching, Peter A
Moore, Adam
de Courcy, Joanna
Pathak, Purnima
Haftchenary, Sina
Aubel, Dawn
Schumacher-Wulf, Eva
author_sort Cardoso, Fatima
collection PubMed
description BACKGROUND: Quality of life (QOL) is a critical factor in decision-making for advanced breast cancer (ABC). There is a need to improve how QOL and treatment-related side effects (SEs) that impact it are clinically assessed. We examined healthcare professionals’ (HCPs’) and patients’ perspectives on the importance of QOL discussions and the impact of SEs on QOL in clinical settings. PATIENTS AND METHODS: A cross-sectional online survey was conducted (7/2020-5/2021) among oncologists, nurses, and patients with HR+/HER2− ABC in 7 countries. RESULTS: The survey was completed by 502 HCPs and 467 patients. Overall, 88% of oncologists and 49% of patients recalled QOL discussions at follow-up. In the first- through fourth-line (1L, 2L, 3L, and 4L) settings, respectively, 48%, 57%, 79%, and 85% of oncologists reported QOL was very important; 73% and 45% of patients receiving 1L and 2L treatment and 40% receiving 3L+ treatment indicated QOL was important. Patients reported that insomnia, anxiety, back pain, fatigue, diarrhea, hot flashes, low sexual interest, and loss of appetite had a moderate/severe impact on QOL. Of patients experiencing certain SEs, ≥64% did not discuss them with HCPs until there was a moderate/severe impact on QOL. In patients receiving a CDK4/6 inhibitor, SEs, including insomnia, diarrhea, back pain, and fatigue, had a moderate/severe impact on QOL. CONCLUSIONS: This survey discovered disconnects between HCPs and patients with ABC on the importance of QOL discussions and the impact of SEs on QOL. These data support the use of ABC-specific QOL questionnaires that closely monitor SEs impacting QOL.
format Online
Article
Text
id pubmed-10546820
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105468202023-10-04 Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey Cardoso, Fatima Rihani, Julie Harmer, Victoria Harbeck, Nadia Casas, Ana Rugo, Hope S Fasching, Peter A Moore, Adam de Courcy, Joanna Pathak, Purnima Haftchenary, Sina Aubel, Dawn Schumacher-Wulf, Eva Oncologist Breast Cancer BACKGROUND: Quality of life (QOL) is a critical factor in decision-making for advanced breast cancer (ABC). There is a need to improve how QOL and treatment-related side effects (SEs) that impact it are clinically assessed. We examined healthcare professionals’ (HCPs’) and patients’ perspectives on the importance of QOL discussions and the impact of SEs on QOL in clinical settings. PATIENTS AND METHODS: A cross-sectional online survey was conducted (7/2020-5/2021) among oncologists, nurses, and patients with HR+/HER2− ABC in 7 countries. RESULTS: The survey was completed by 502 HCPs and 467 patients. Overall, 88% of oncologists and 49% of patients recalled QOL discussions at follow-up. In the first- through fourth-line (1L, 2L, 3L, and 4L) settings, respectively, 48%, 57%, 79%, and 85% of oncologists reported QOL was very important; 73% and 45% of patients receiving 1L and 2L treatment and 40% receiving 3L+ treatment indicated QOL was important. Patients reported that insomnia, anxiety, back pain, fatigue, diarrhea, hot flashes, low sexual interest, and loss of appetite had a moderate/severe impact on QOL. Of patients experiencing certain SEs, ≥64% did not discuss them with HCPs until there was a moderate/severe impact on QOL. In patients receiving a CDK4/6 inhibitor, SEs, including insomnia, diarrhea, back pain, and fatigue, had a moderate/severe impact on QOL. CONCLUSIONS: This survey discovered disconnects between HCPs and patients with ABC on the importance of QOL discussions and the impact of SEs on QOL. These data support the use of ABC-specific QOL questionnaires that closely monitor SEs impacting QOL. Oxford University Press 2023-07-31 /pmc/articles/PMC10546820/ /pubmed/37523663 http://dx.doi.org/10.1093/oncolo/oyad207 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Breast Cancer
Cardoso, Fatima
Rihani, Julie
Harmer, Victoria
Harbeck, Nadia
Casas, Ana
Rugo, Hope S
Fasching, Peter A
Moore, Adam
de Courcy, Joanna
Pathak, Purnima
Haftchenary, Sina
Aubel, Dawn
Schumacher-Wulf, Eva
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
title Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
title_full Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
title_fullStr Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
title_full_unstemmed Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
title_short Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
title_sort quality of life and treatment-related side effects in patients with hr+/her2− advanced breast cancer: findings from a multicountry survey
topic Breast Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546820/
https://www.ncbi.nlm.nih.gov/pubmed/37523663
http://dx.doi.org/10.1093/oncolo/oyad207
work_keys_str_mv AT cardosofatima qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT rihanijulie qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT harmervictoria qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT harbecknadia qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT casasana qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT rugohopes qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT faschingpetera qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT mooreadam qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT decourcyjoanna qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT pathakpurnima qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT haftchenarysina qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT aubeldawn qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey
AT schumacherwulfeva qualityoflifeandtreatmentrelatedsideeffectsinpatientswithhrher2advancedbreastcancerfindingsfromamulticountrysurvey